Willow Biosciences Inc Stock Price, News & Analysis

Willow Biosciences has appointed Dr. Peter Seufer-Wasserthal as Interim President and CEO as of July 17, 2022, following the retirement of Trevor Peters. Dr. Seufer-Wasserthal, previously the Chairman of the Board, aims to lead the company in expanding its product portfolio and forging strategic partnerships. Barbara Munroe has been appointed as Lead Independent Director. Willow's commitment to developing sustainable, high-purity ingredients positions it for growth in the biotech sector, particularly in nutrition, food and beverage, and consumer care markets.

Willow Biosciences Inc. (CANSF) announced significant developments on May 11, 2022. The company entered a Manufacturing Services Agreement with a second Contract Development and Manufacturing Organization (CDMO), enhancing its fermentation production capacity for FutureGrown™ products, including cannabigerol (CBG). In addition, Willow has completed the initial Stage 1 toxicological assessment of FutureGrown™ CBG, indicating it is non-mutagenic, a crucial step towards obtaining Generally Recognized as Safe (GRAS) status in the United States.

Willow Biosciences Inc. (OTCQB: CANSF) announced a live webcast investor presentation on February 3rd, 2022, at 2:00 PM EST. President and CEO Trevor Peters will discuss key business areas and engage with investors through a Q&A session. Interested participants must pre-register for the event through the provided link. An archived version of the presentation will be accessible on the company's website afterward. Willow specializes in sustainable cannabinoid production using its FutureGrown™ platform, aiming to benefit various markets.

Willow Biosciences has announced positive results from its first peer-reviewed study on cannabigerol (CBG), detailing its benefits for skincare. Conducted with Signum Biosciences, the study showcased that Willow's FutureGrown CBG significantly reduces skin inflammation and improves barrier function in a clinical trial involving 20 participants. These findings highlight CBG's promise as a skincare ingredient, outperforming cannabidiol (CBD) in several aspects. The study's publication in the journal Molecules adds credibility to Willow's ongoing research in the cannabinoid industry.

Willow Biosciences reported its financial results for Q3 2021, emphasizing significant operational advancements and strong liquidity with $35.7 million in cash. The company highlighted a >400% increase in production titer for cannabigerol (CBG) and announced the addition of cannabinol (CBN) to its development program. Willow also formed an ESG committee to oversee sustainability efforts. The company aims to secure supply agreements and advance its cannabinoid product portfolio, leveraging favorable regulatory changes and its leading position in the biosynthetic cannabinoid market.

Willow Biosciences (CANSF) provided updates on its operations as of Sept. 21, 2021. The company completed its first commercial fermentation run of CBG in March 2021, increasing production titer by over 400%. CBG samples were delivered to Cellular Goods PLC in July 2021. Willow has also developed a process for producing cannabigerolic acid (CBGA), now available for customer evaluation. However, the company faces a patent infringement claim related to CsPT1, which it states is without merit, as it does not use this enzyme in its processes.

Willow Biosciences has entered a multi-year supply agreement with Cellular Goods to provide ultra-pure, biosynthetically produced cannabigerol (CBG) for use in skincare products set to launch in autumn 2021. The first shipment is scheduled for July 2021. Willow's CBG has demonstrated safety and beneficial properties on human skin, making it a suitable ingredient for cosmetics in the evolving UK market, where CBG is now approved for use. This agreement marks Willow's first commercial supply of CBG, enhancing its position in the growing cannabinoid sector.

Willow Biosciences Inc. (CANSF) announced participation in a panel at SynBioBeta's conference on May 26, 2021, focusing on synthetic biology in biopharma. The event features industry leaders discussing advancements in bioproduction. Willow, specializing in sustainable cannabinoid production through yeast-based biosynthesis, aims to showcase its innovative approaches. This participation supports Willow's ongoing efforts in the biotech sector, particularly in creating high-purity, plant-derived ingredients.